Jag Capital Management LLC boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,003 shares of the pharmaceutical company’s stock after purchasing an additional 4,397 shares during the period. Vertex Pharmaceuticals comprises 1.6% of Jag Capital Management LLC’s holdings, making the stock its 29th largest position. Jag Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $9,750,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. Resources Investment Advisors Inc. bought a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at $27,000. We Are One Seven LLC bought a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at $32,000. Berman Capital Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at $35,000. Sontag Advisory LLC bought a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Quantamental Technologies LLC bought a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at $41,000. 95.37% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have issued reports on VRTX. Evercore ISI began coverage on Vertex Pharmaceuticals in a research note on Thursday. They issued an “in-line” rating and a $183.00 target price on the stock. William Blair upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $183.85 target price on the stock in a research note on Tuesday, March 26th. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Svb Leerink restated a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, March 19th. Finally, Leerink Swann lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $185.40 target price on the stock. in a research note on Tuesday, March 19th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $203.31.
Shares of NASDAQ:VRTX traded down $0.29 during midday trading on Monday, reaching $182.49. 787,605 shares of the company traded hands, compared to its average volume of 1,438,299. Vertex Pharmaceuticals Incorporated has a 12 month low of $144.07 and a 12 month high of $195.81. The firm has a market cap of $46.73 billion, a price-to-earnings ratio of 64.48, a PEG ratio of 2.71 and a beta of 1.64.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Tuesday, February 5th. The pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.24. Vertex Pharmaceuticals had a return on equity of 24.15% and a net margin of 68.81%. The company had revenue of $870.11 million for the quarter, compared to analyst estimates of $818.29 million. During the same period in the previous year, the company posted $0.61 EPS. The firm’s revenue for the quarter was up 33.5% compared to the same quarter last year. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 3.04 EPS for the current fiscal year.
In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 111,431 shares of the company’s stock in a transaction dated Monday, February 11th. The stock was sold at an average price of $180.24, for a total value of $20,084,323.44. Following the transaction, the chief executive officer now directly owns 223,916 shares in the company, valued at approximately $40,358,619.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Reshma Kewalramani sold 1,488 shares of the company’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $186.94, for a total value of $278,166.72. Following the completion of the transaction, the chief marketing officer now owns 14,038 shares in the company, valued at $2,624,263.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 208,624 shares of company stock worth $38,187,166. 0.75% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by Jag Capital Management LLC” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dispatchtribunal.com/2019/04/15/vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-jag-capital-management-llc.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Recommended Story: What is the Current Ratio?
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.